Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Pass Above Fifty Day Moving Average – Should You Sell?

Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $20.28 and traded as high as $22.2775. Hikma Pharmaceuticals shares last traded at $22.2775, with a volume of 200 shares changing hands.

Analysts Set New Price Targets

Separately, Citigroup began coverage on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Hikma Pharmaceuticals Price Performance

The company has a quick ratio of 1.06, a current ratio of 1.82 and a debt-to-equity ratio of 0.57. The stock has a 50 day simple moving average of $20.28 and a 200 day simple moving average of $19.47.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.